| Target Price | NZ$39.51 |
| Price | NZ$37.69 |
| Potential |
4.84%
register free of charge
|
| Number of Estimates | 12 |
|
12 Analysts have issued a price target Fisher & Paykel Healthcare 2026 .
The average Fisher & Paykel Healthcare target price is NZ$39.51.
This is
4.84%
register free of charge
NZ$42.95
13.94%
register free of charge
NZ$29.29
22.29%
register free of charge
|
|
| A rating was issued by 15 analysts: 6 Analysts recommend Fisher & Paykel Healthcare to buy, 7 to hold and 2 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Fisher & Paykel Healthcare stock has an average upside potential 2026 of
4.84%
register free of charge
|
| Mar '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion NZ$ | 2.02 | 2.27 |
| 15.96% | 12.27% | |
| Net Margin | 18.66% | 19.22% |
| 145.31% | 2.98% |
15 Analysts have issued a sales forecast Fisher & Paykel Healthcare 2026 . The average Fisher & Paykel Healthcare sales estimate is
This results in the following potential growth metrics:
15 Fisher & Paykel Healthcare Analysts have issued a net profit forecast 2026. The average Fisher & Paykel Healthcare net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Mar '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share NZ$ | 0.64 | 0.74 |
| 178.26% | 15.63% | |
| P/E | 51.15 | |
| EV/Sales | 9.86 |
15 Analysts have issued a Fisher & Paykel Healthcare forecast for earnings per share. The average Fisher & Paykel Healthcare EPS is
This results in the following potential growth metrics and future valuations:
Fisher & Paykel Healthcare...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


